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Prostaglandins (PG) regulate many biological processes, among others inflammatory reactions. Cyclooxygenases-1 and -2 (COX-1 and COX-2)
catalyse PG synthesis. Since this step is rate limiting, the regulation of COX expression is of critical importance to PG biology. Contrary to COX-1,
which is constitutively expressed, COX-2 expression is subject to regulation. For example, COX-2 levels are increased in inflammatory reactions.
Many signalling pathways can regulate COX-2 expression, not least those involving receptors for COX products themselves. Analysis of the
intracellular signal transducers involved reveals a crucial role for cAMP, albeit as a modulator rather than direct inducer. Indeed, the influence of
cAMP on COX-2 expression is complex and dependent on the cell type and cellular environment. This review aims to summarise various topics
related to cAMP-dependent COX-2 expression. Firstly, the main aspects of COX-2 regulation are briefly considered. Secondly, the molecular basis
for COX-2 gene (post)-transcriptional regulation is reviewed. Lastly, a detailed overview of the effects of cAMP-dependent signalling on COX-2
mRNA and protein expression in various human and rodent cells is provided. There is a large number of marketed, clinical and preclinical concepts
promoting the elevation of intracellular cAMP levels for therapeutic purposes (e.g., β2-agoinsts, PG receptor agonists, phosphodiesterase inhibitors).
In this respect, the role of cAMP in the regulation of COX-2 expression, especially the human enzyme, is of significant clinical importance.
© 2007 Elsevier B.V. All rights reserved.Keywords: cAMP; Adenylate cyclase; Prostaglandin; cAMP-responsive element; cGMP; Phosphodiesterase1. Introduction
1.1. Prostanoid signalling
Prostanoids (PGF2α, PGE2, PGD2, PGI2, TxA2) are derived
from arachidonic acid (AA) via a sequence of enzyme-catalysed
steps, involving in order phospholipase A2, Cyclooxygenases-1
and -2 (COX-1 and -2) and one of several terminal prostaglandin
synthases. The COX catalysed step results in the formation of
PGH2 and is rate limiting. Hence, levels of COX expression are a
critical determinant of prostanoid levels.
Of the two COX isozymes, one is constitutively expressed,
COX-1, while the other, COX-2, is regulated. Many cytokines
and growth factors govern COX-2 regulation (for a review, seeAbbreviations: PG, prostaglandins; COX, cyclooxygenases; cAMP, cyclic a
db-cAMP, di-butyryl-cAMP; LPS, lipopolysaccharide; CRE, cAMP-responsive elemen
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doi:10.1016/j.bbamcr.2007.09.001[1]). These signalling mediators use several different intracel-
lular pathways, e.g., NFkB, fos/jun. While those pathways can
influence COX-2 expression directly by acting on their respec-
tive sites on the COX-2 promoter, they also do so indirectly via
the modulation of cAMP signalling. For instance PKA function
might be modulated (see Fig. 1). Furthermore, other signalling
pathways involved in COX-2 levels regulation act by directly
affecting cAMP levels. For instance ligands for Gi- or Gs-
coupled GPCR receptors influence cAMP levels directly by
modulating adenylate cyclase activity: Gi-coupled receptors
inhibit adenylate cyclase activity while Gs-coupled receptors
stimulate it. Indeed, this is illustrated by COX-2 autoregulatory
mechanisms involving the whole PG pathway: prostaglandin E2
signals through four different G-protein-coupled receptors (e.g.,denosine mono-phosphate; AC, adenylate cyclase; AA, arachidonic acid;
t; CREB, cAMP-responsive element binding protein; PDE, phosphodiesterase
rg, Germany. Tel.: +49 6421 2862667; fax: +49 6421 2868956.
Fig. 1. Illustration of PG mediated induction of Cox-2 via adenylate cyclase pathway and synergistic action with cAMP mimetics.
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COX-2 promoter activity (Table 2).EP receptors). EP2 and EP4 receptors are Gs-coupled GPCRs
and promote an increase in cAMP levels. EP3 receptor is Gi
coupled and promotes a decrease in cAMP levels [2]. Cell-
specific pattern of expression these receptors thus results in
either an increase or decrease in cAMP levels when PGE2 is
present. This in turn will have an effect on COX-2 expression
levels, as we will see later (see Fig. 1). While some signalling
pathways might influence cAMP levels by interfering with its
production, others may do so by affecting its degradation by
stimulating or inhibiting phosphodiesterases (PDEs). Indeed,
just as the receptor pattern governs the cell response to mediators
from the point of view of COX expression, the cellular PDE
expression pattern is also of great importance since it determines
how a cAMP response is dampened and stopped (see Fig. 1).
1.2. Molecular aspects of COX-2 regulation
COX-2 was discovered in 1991 as a primary response gene
[3,4]. COX-2 expression is regulated by both transcriptional
and post-transcriptional mechanisms. The human COX-2 gene
maps to chromosome 1 q25.2–q25.3 [5]. It is approximately
8.3 kb long and comprises 10 exons (see Fig. 2a). Three
mRNA transcript variants have been reported, they are
respectively 2.8, 4,0, and 4.6 kb in length. The largest exon
in the COX-2 gene encodes the entire 3′-untranslated region
(3′-UTR). The latter contains several copies of the “ATTTA”
RNA instability element (see Fig. 2c). Sequence analysis of the
5′-flanking region reveals several potential transcription
regulator elements (see Fig. 2b). However, in all studied
species, only a limited number of elements, namely the cAMP
response element (CRE), the C/EBP-NF-IL6 (“CAAT/enhancer
binding protein”), NFAT (“nuclear factor of activated T cells”)
and NFkB (“nuclear factor kappa B cells”) sites, and the E-box are known to be involved in the regulation of COX-2
gene expression (see Tables 1 and 2 for transcription factor
binding sites and abbreviations). Differences exist between
murine and human COX-2 promoters (see Fig. 2b): for example,
the proximal promoter region of murine COX-2 has a single
NFkB site, whereas the human gene has two putative NFkB
sites [1].
1.3. Transcriptional regulation of COX-2
The CRE response element has been identified as one of the
central regulatory elements in the COX-2 promoter region [1].
Several studies analyzed the effects of various signalling
pathway, which do not activate cAMP generation, but do lead
to gene transcription through the CRE site of the COX-2 gene.
Homo- or hetero-dimers of c-fos, c-jun, ATF family members of
blip proteins can bind to this CRE response element often
leading to the activation of COX-2 expression. The following
examples illustrate induction ofCOX-2 gene expression through
various cAMP-independent pathways that ultimately signal
through the CRE site.
Schroer et al. [6] mutated the CRE site in a −891/+9 human
COX-2 promoter fragment from −59-TTCGTCA-53 (CRE-
wild type, WT) to 59-TTgagCA-53 (CRE-mutant, M). Com-
pared to CRE-WT basal promoter activity of CRE-M was
significantly reduced. CRE-M abrogated the activity stimulated
by PMA, IL-1β, or TNFα in human endothelial cells and human
foreskin fibroblasts. Double mutants containing both CRE-M
and C/EBP-M (due to the high sequence homology between the
C/EBP and CRE response elements, C/EBP also serves as a
binding site for cAMP-induced transcription) did not further
reduce promoter activity, indicating the dominant role of CRE in
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COX-2 by ceramides in 185B5/HER cells, a human mammary
epithelial cell line. Ceramides (both C2 and C6− ceramide,
10 μM) induced COX-2 mRNA and protein expression. In
order to identify the mechanism by which ceramide upregulates
the transcription of the COX-2 gene, wild-type “full-length”
(−1432/+59) human COX-2 promoter constructs vs. mutagen-
ized or truncated versions were transiently transfected into
185B5/HER cells. These promoter studies indicate that the CRE
site is critical for transcriptional regulation of the COX-2 gene
by ceramides. Further work revealed that ceramide exposure
increased MAPK signalling an activator of c-Jun. The latter
induces COX-2 gene transcription via the CRE site.
Kirtikara and co-workers [8] examined the transcriptional
regulation of COX-2 in the human microvascular endothelial
cell line HMEC-1 treated with IL-1β. In their experiments, they
used a wild-type “full-length” (−1432/+59) human COX-2
promoter construct or, mutagenized or truncated versions. All
truncated constructs exhibited similar activity as the wild type
constructed, except for the most extensively truncated constructs
were all three AP-2, NF-IL6, and CRE sites were missing thus
demonstrating their requirement for IL-1β-induced COX-2
promoter activity.
Inoue and co-workers [9] analyzed the COX-2 gene ex-
pression induced by fluid shear stress in human umbilical vein
endothelial cells (HUVECs) and bovine arterial endothelial
cells (BAECs). They could show that laminar shear stress
induces COX-2 mRNA in HUVECs approximately 4-fold over
controls. Using a transiently transfected human COX-2 gene
promoter (−327/+59) they could demonstrate that shear stress
also increases COX-2 promoter activity in BAECs. Mutations
in the CRE site but not the NFkB or NF-IL6 sites significantly
reduced shear stress-induced human COX-2 promoter activity.
Electrophoretic mobility shift assays (EMSA) showed specific
binding of nuclear extracts to labelled oligos containing the
CRE site which was enhanced following exposure to shear
stress. Both approaches demonstrate the critical role of the CRE
site in shear stress-induced COX-2 expression.
Wu and colleagues [10] investigated the expression of COX-
2 in primary cultures of normal and endometriotic human stro-
mal cells. Expression levels of COX-2 mRNA and protein levels
in ectopic endometriotic implants obtained from patients with
pelvic implant and ovarian endometrioma were much greater
than in eutopic endometrium of endometriosis-free women. In
contrast to stromal cells derived from normal endometrium,
IL-1β not only increased COX-2 mRNA stability but also
upregulated COX-2 promoter activity in ectopic endometriotic
stroma. Induction of COX-2 promoter activity by IL-1β is
mediated via mitogen-activated protein (MAP) kinase-depen-
dent phosphorylation of cAMP-responsive element binding
protein (CREB). Promoter activity and electrophoretic motility
shift assays demonstrate that a CRE site located at−571/−564 of
COX-2 promoter is critical for IL-1β-induced COX-2 gene
expression. The importance of the −571/−564 CRE site is
unusual given that all other studies utilizing human COX-2
promoter constructs suggest that the −59/53 CRE site is the
relevant site. However, two independent approaches support arole of CRE −571/−564. First truncated promoter constructs
leaving −550/−49 were unresponsive to IL-1β. Second, site-
directed mutagenesis of the CRE located at −571/−564
abrogates IL-1β-induced COX-2 promoter activity; and third,
EMSA data (direct binding and specific competition) demon-
strated that CREB directly binds to the CRE site of this region.
There is a 5-fold increase of COX-2 mRNA expression
levels upon treatment of normal human epidermal keratinocytes
(NHEK) with TGF-alpha (50 ng/ml) [11]. Deletion and mu-
tation analysis indicated the importance of the proximal CRE
site in the transcriptional control of this gene by TGF-α. The
increase in COX-2 mRNA by TGF-α requires activation of both
the extracellular signal-regulated kinase (ERK) and p38
mitogen-activated protein kinase (MAPK) pathways. Inhibition
of p38 MAPK decreases the stability of COX-2 mRNA, while
inhibition of MAPK/ERK kinase (MEK) does not. These results
suggest that the p38 MAPK signalling pathway controls COX-2
at the level of mRNA stability, while the ERK signalling path-
way regulates COX-2 at the level of transcription.
1.4. Post-transcriptional regulation
The abovementioned mechanisms (regulation of mRNA
stability and translation) have been reported to be crucially
involved in the regulation of COX-2 expression [12]. Exon 10 of
the cyclooxygenase-2 gene encodes the entire 3′-UTR (Fig. 2),
and contains several copies of the pentameric ATTTA sequence.
The AUUUA motif (also called AU-rich element — ARE) is
found in the 3′-UTR of many unstable cytokine- and proto-
oncogene-encoding mRNAs, and these motifs regulate mRNA
stability and translation [13]. Involvement of these ARE in the
post-transcriptional regulation of COX-2 expression has been
reported [12,14]. Interestingly a small fragment of the human
COX-2 3′-UTR (CR1; +1 to +123 of the 3′-UTR) containing 6
AREs was sufficient to destabilize a reporter mRNA in trans-
fection assays. These AREs have been shown to regulate gene
expression by interaction with different RNA-binding proteins
[15]. Important RNA-binding proteins shown to bind to COX-2
AREs and to regulate COX-2 expression (mRNA stability or
translatability) are AUF1, HuR, TIA-1, β-catenin, CUGBP2,
TIAR and TTP [16–19]. Interestingly, the overexpression of
COX-2 in most colon carcinoma cells seems to be promoted by a
parallel enhanced expression of the ARE-mRNA stabilizing
protein HuR [20].
ARES aside, other sequence elements of the human COX-2
mRNA have been shown to be involved in the post-transcrip-
tional regulation of COX-2 protein expression. For instance,
transfection experiments using the 3′-UTR of the human COX-2
mRNAwith or without the AREs (ΔARE) demonstrated that the
AREs play a role in the IGF-1-mediated enhancement of COX-2
mRNA stability [21].
Depending on the cell type analyzed, different signalling
pathways (MAPK, AMPK, PKC, PI3K etc., alone or in com-
bination) are involved in regulating COX-2 expression at the
post-transcriptional level [22]. These signalling pathways direct-
ly or indirectly regulate the activity, localization or expression of
several of the RNA-binding proteins discussed above.
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Table 1
Transcription factor binding sites described in the literature
Binding site Position References
Human promoter
AP1 −1596/−1576 [62]
GAS −895/−877 [63]
GAS −850/−831 [63]
HRE −608/−603 [64]
SRE −422 [65]
SP1 −270/−265 [1,66]
NFkB −447/−438 [67]
NFkB −223/−214 [1,67,68]
ETS 5× −170/+50 [69]
C/EBP (CAAT-box) −132/−124 [1,6,8,68,70]
NFAT −105/−97 [71–73]
AP2 −97/−89 [70]
NFAT −76/−71 [71–73]
PEA3 −75/−73 [74]
AP1 −66/−58 [75]
CRE −59/−53 [1,6,8,68,70]
E-box −54/−49 [68,70]
Mouse promoter
ISRE −1541/−1522 [76,77]
ISRE −1215/−1206 [76,77]
YY1 −796/−780 [78]
ETS −725/−734 [21]
CRE −433/−428 [79,80]
NFkB −401/−393 [81,82]
ETS −320/−329 [21]
Cbfa1 −267/−261 [83]
AhR −167 [56]
AP2 −150/−142 [81]
C/EBP −138/−132 [79,81,82,84–87]
C/EBP −93/−85 [56,79,82]
AP1 −67/−62 [79,80,88]
CRE −59/−52 [56,79,82,89,90]
E-box −52/−47 [79,80,82,89,90]
Rat promoter
C/EBP −139/−131 [91]
NFAT −75/−70 [92]
E-box −54/−49 [91]
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Modulation of COX-2 transcriptional regulation by cAMP in
different cell types was investigated in various ways. On the one
hand researchers have used endogenous mechanisms such asSeveral pro-inflammatory stimuli, which induce COX-2gene
expression, also stimulate MAPK. In particular, the activation of
p38MAPK has been shown to be critically involved in the post-
transcriptional regulation of several pro-inflammatory genes
[23]. Furthermore, p38MAPK has been shown to regulate the
localization and activity of several RNA-binding proteins
involved in post-transcriptional control of COX-2 expression
[15]. Accordingly, specific inhibitors of p38 block the
accumulation of COX-2 mRNA in a variety of cells subjected
to pro-inflammatory signals. In Hela cells stimulated with IL-1αFig. 2. (a) Structure of the human COX-2 gene. Shown are the exons (E1 to E10), the s
of the gene. (b) Comparison of transcription factor binding sites in the 5′-flanking
transcription factor binding sites described in the literature are shown in blue or red. B
red. Putative transcription factor binding sites found by P-MATCH (http://www.ge
black. (c) Structure of the exon 10 and 3′-UTR of the human COX-2 gene. Shown
(CR1).and β, and in primary human monocytes stimulated with LPS,
inhibition of p38 results in a rapid and specific destabilization of
COX-2 mRNA but has little effect on COX-2 transcription.
Similar findings of p38 activation on mRNA stability were
reported in human monocytes as well as myofibroblasts [24,25].
In addition to p38MAPK, ERK1/2 and JNK have also been
shown to be involved in the post-transcriptional regulation of
COX-2 expression in some cell types. The post-transcriptional
regulation of COX-2 expression by bile acid and ceramide in rat
intestinal epithelial cells [26] and IGF in human ovarian cancer
cells [21] has been shown to depend on ERK1/2. However, the
exact mechanisms (e.g., RNA-binding proteins involved) have
not been determined. In murine J774 macrophages, specific
inhibition of JNK by SP600125 resulted in reduction of LPS-
induced COX-2 expression by destabilization of the COX-2
mRNA [27]. JNK activity has been shown to modulate
Tristetraprolin (TTP) expression [28] and TTP destabilizes the
COX-2 mRNA [17,18]. However, whether the SP600125-
mediated modulation of TTP expression is involved in the
SP600125-dependent inhibition of LPS-induced COX-2 ex-
pression in J774 macrophages is not known.
In addition to MAPK, other signalling pathways seem to be
involved in the post-transcriptional regulation of COX-2 expres-
sion in different cell types. In human ovarian cancer cells IGF-1-
induced stabilization of the COX-2 mRNA depends on the
activation of PI3K and PKC in addition to the activation of
ERK1/2 and p38MAPK [21]. Furthermore, in human mesangial
cells the ATP-induced stabilization of the COX-2 mRNA is
inhibited by PKC inhibitors or specific downregulation of PKC-
α by siRNAs. Interestingly, in this cell type ATP incubation
induces PKCα-dependent HuR phosphorylation, which results
in enhanced nuclear to cytoplasmic shuttling of HuR and in turn
in stabilization of COX-2 mRNA [29].
Activation of the AMP-activated kinase (AMPK) has been
shown to reduce COX-2 expression [30]. AMPK has been
shown to regulate the nucleo-cytoplasmic shuttling of HuR.
Activation of AMPK reduces cytoplasmic HuR levels [31].
However, whether AMPK-activation reduces COX-2 mRNA
stability has not been determined.
Most studies addressing the role of cAMP signalling in
human cells used a combination of pro-inflammatory signals
and various cAMP modifiers. The results of these studies are
summarized in Table 3.
2. Effects of cAMP signalling on COX-2 expressiontart codon (ATG), the top codon (STOP) and the 3′-untranslated region (3′-UTR)
sequences (promoter) of the human, murine and rat COX-2 gene. Functional
inding sites of transcription factor known to be regulated by cAMP are shown in
ne-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi) are shown in
are the top codon (STOP), the AU-rich sequences (AU) and the CR1 fragment
Table 2
Abbreviations used
Abbreviation Description
3′-UTR 3′-Untranslated region of the human COX-2 mRNA
AhR Aryl hydrocarbon receptor
AP-1 Activating protein-1
AP-2 Activating protein-2
AP-4 Enhancer binding factor AP-4
AREB6 Atp1a1 regulatory element binding protein 6
ARP-1 Apolipoprotein AI regulatory protein
ATF Activating transcription factor
ATG Start codon
AU AU-rich element (AUUUA or AUUUUA)
BSAP B-cell-specific activator protein
Cbfa1 Core binding factor a1
CDP CCAAT displacement protein;
C/EBP (NF-IL6) CAAT/Enhancer binding protein
COUP-TF Chicken ovalbumin upstream promoter transcription factor
CR1 3′-UTR fragment of the human COX-mRNA with 6 ARE
CRE cAMP response element
CREB cAMP response element-binding protein
c-Rel Nuclear factor kappa B c-Rel
c-Rel Nuclear factor kappa B c-Rel
E1–E10 Exons of the human COX-2 gene
E2F Adenovirus E2 promoter binding factor
E47 Helix–loop–helix protein
Elk-1 Ets-related protein
ETS Avian E26 (E-twenty-six) retrovirus encoded
transcription factor
Evi-1 Evi-1 zinc finger myeloid transforming gene
GAS γ-Activated site
ISRE Interferon stimulated response element
HFH-1 HNF-3/Forkhead-like protein 1
HLF Hepatic leukemia factor
HNF-4alpha1 Hepatocyte nuclear factor 4alpha1
HRE HIF-1-responsive element
NF-1 Nuclear factor-1
NF-IL6 Nuclear factor-1
NFAT Nuclear factor of activated T cells
NFkB Nuclear factor kappa B cells
NFkB p50 Nuclear factor kappa B p50
NFkB p65 Nuclear factor kappa B p65
Nkx2-5 Cardiac-specific homeobox protein
NRF-2 Nuclear respiratory factor 2
PEA3 Polyomavirus enhancer activator 3
RREB-1 Ras-responsive element binding protein 1
SP1 Stimulating protein-1
SRE Sterol response element
STAT Signal transducer and activator of transcription
STOP Stop codon
XBP-1 X-box binding protein 1
XFD-1 Xenopus fork head domain factor-1
XFD-2 Xenopus fork head domain factor-2
YY1 Ying yang 1
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intracellular cAMP signalling pathway was manipulated via
direct activation of adenylate cyclase (using forskolin or cholera
toxin) and inhibition of cAMP degradation using selective and
unselective phosphodiesterase inhibitors (PDEi, i.e., rolipram,
IBMX, respectively). Membrane-permeable cAMP analogues
such as dibutyryl cAMP (db-cAMP) and 8-bromo-cAMP and
inhibition of phosphatases with okadaic acid have also been
used (Fig. 1).2.1. Leukocytes
There is consistent evidence that the cAMP pathway exerts a
positive modulatory role on COX-2 induction in primary human
cells (see Table 3). Hinz and colleagues [32] analyzed the effects
of cAMP modifiers on the expression of cyclooxygenase-2 in
human primary monocytes from healthy volunteers exposed to
LPS. Alone, db-cAMP (100 μM) did not stimulate PGE2
generation in monocytes, however, in combination with LPS
(10 μg/ml) it led to a 2-fold increase of both PGE2 levels and
COX-2 mRNA levels. Likewise, cholera toxin (10 μg/ml) and
IBMX (300 μM), respectively, led to 3-fold increase of both
PGE2 and COX-2 mRNA levels when given in presence of LPS.
Furthermore, activation of Gs-coupled EP receptors (EP2/4)
increased COX-2 mRNA levels (10 μM Butaprost, agonist for
EP2; 10 μM 11-deoxy PGE1, agonist for EP2/4) in monocytes
stimulated with LPS. In contrast, sulprostone (10 μM) acting on
EP1 and EP3 receptors did not further augment COX-2 mRNA
levels. Furthermore, results reported by Juergens and colleagues
indirectly confirm the positive modulatory role for cAMP on
COX-2 regulation. They determined the effects of PDE inhi-
bition by theophylline on cAMP and LTB4 and PGE2 produc-
tion, in cultured monocytes in vitro obtained from healthy non-
smoking donors [33]. LPS-stimulated generation (10 μg/ml) of
intracellular cAMP increased significantly (+162%) in the
presence of theophylline (18 μg/ml); production of LTB4 was
suppressed (−42%) compared to the baseline, whereas PGE2
production increased significantly (+39%). Production of cAMP
correlated with increased PGE2 production and with suppression
of LTB4. These effects were mimicked by db-cAMP but not by
dibutyryl-cGMP. Interestingly, these effects could be abolished
by ibuprofen suggesting that the underlying mechanism is a
feedback regulatory induction of COX-2 by a prostaglandin-
driven cAMP-mediated process (possibly involving the EP2/4
receptors). These results provide evidence that the clinical
efficacy of theophylline may also result from inhibition of leu-
kotriene production and its ability to stimulate PGE2 production.
Results by Inoue and Tanabe [34] using the human U937
monocytic cell line could not confirm the positive modulatory
role of cAMP on COX-2 transcriptional regulation. In U937
cells differentiated to a monocytic phenotype with PMA and
LPS COX-2 mRNA levels were increased 18-fold as compared
to undifferentiated controls. Db-cAMP (100 μM) alone or in
combination with LPS did not further increase COX-2 mRNA
levels, compared to their respective controls. This would tend to
suggest that U937 is not completely suitable as a model for
monocytes. Beusenberg and co-workers [35] analyzed the effect
of 1 mM IBMX, 10 μM salbutamol and 1 mM sodium
nitroprusside on PGE2 and LTB4 release as well as on cAMP and
cGMP levels in human alveolar macrophages obtained from
controls and COPD patients. In both populations IBMX
increased cAMP level by 55… 93% and salbutamol… IBMX by
285… 352%. Except for the 61% rise in LTB4 release by
salbutamol… IBMX the drugs hardly affected PGE2 and LTB4
release from control macrophages. In COPD alveolar macro-
phages, however, IBMX and salbutamol… IBMX largely reduced
PGE2 release (63 vs. 11 pg per 10
6 cells) but less efficiently
Table 3
Effects of cAMP-modifiers on COX-2 induction
Cell type COX-2 inducer cAMP modifier COX-2 expression References
Human leucocytes and macrophages
hMonozytes LPS db-cAMP, IBMX, PGE2 ↑, COX2-mRNA: ↑ [32]
Cholera toxin
LPS 11-Deoxy-PGE1, butaprost PGE2 ↑, COX-2 mRNA: ↑
LPS Sulprostone COX-2 mRNA: ↔
hMonozytes LPS Theophyllin PGE2 ↑ [33]
hMonozytes LPS db-cAMP PGE2 ↑
hAlv. Macrophages IBMX, salbutamol PGE2 ↔ [35]
COPD hAlv. Macrophages IBMX, salbutamol PGE2 ↓
U937 db-cAMP, Promoter: ↔, mRNA: ↔ [34]
U937 LPS db-cAMP, Promoter: ↔, mRNA: ↔
PMN fMLP forskolin+RO 20–1724 mRNA: ↑, protein: ↑ [36]
fMLP S-P-cAMP mRNA: ↑, protein: ↑
S-P-cAMP protein: ↔, mRNA: ↔
Jurkat α−CD3 & α−CD28, wt-promoter: ↑, with NFAT site: ↔ [37]
α−CD3 & α−CD28 Rolipram, etazolate, Ro 20–1724 wt-Promoter: ↓,
α−CD3 & α−CD28 db-cAMP, forskolin wt-Promoter: ↑
Mouse macrophages and related cell types
RAW264.7 db-cAMP PGE2 ↑, COX-2 mRNA: ↑ [93]
LPS db-cAMP PGE2 ↑↑, COX-2 mRNA: ↑↑
RAW264.7 LPS/TNF/IL-1β Milrinone, 8br-cAMP COX-2 mRNA: ↑ [59]
RAW264.7 LPS/TNF/IL-1β Amrinone COX-2 mRNA: ↓
LPS mRNA: ↑, protein: ↑, PGE2 ↑ [94]
LPS ANP mRNA: ↓, protein: ↓, PGE2 ↓
Human endothelial cells and smooth muscle
hPASMC Bradykinin Promoter: ↑, promoter with deleted CRE site: ↔ [39]
EP4 (ONO-AE1 329) Promoter: ↑, promoter with deleted CRE site: ↔
PGE2, EP2 (ONO-AE1 259) Promoter: ↑, promoter with deleted CRE site: ↔
hASMC PMA Iloprost mRNA: ↑↑, protein: ↑↑, PGI2 ↑↑ [61]
hASMC Forskolin, db-cAMP, iloprost mRNA: ↑, protein: ↑, PGI2 ↑,
hBSMC IL-1β PGE2, forskolin mRNA: ↑, protein: ↑, PGE2↑ [95]
RASF IL-1β Protein: ↑↑, [42]
IL-1β Rofecoxib Protein: ↑,
IL-1β Rofecoxib, EP2 or EP4 agonist Protein: ↑↑,
Mesangial cells PGE2, db-cAMP mRNA: ↑, protein: ↑, PGE2↑, [44]
HUVEC IL-1β Protein: ↑ [45]
IL-1β PGE2 Protein: ↔
IL-1β PGE2, forskolin Protein: ↑
BAEC LPS Protein: ↑ [46]
LPS db-cAMP Protein: ↑↑
LPS db-cAMP, IBMX Protein: ↑↑↑
Miscellaneous cell types
hKeratinocytes UVB Promoter: ↑ [47]
Forskolin promoter: ↑
mKeratinocytes PGE2, forskolin, db-cAMP protein: ↑ [48]
Rat granulosa cells LH, FSH db-cAMP, CTX, IBMX Protein: ↑, PGE2 [49]
Forskolin Protein: ↑, PGE2
Rat granulosa cells Forskolin Promoter: ↑ [50]
LH, FSH Promoter: ↑
Bovine granulosa cells Forskolin, db-cAMP Promoter: ↑ [51]
Human chondrocytes IL-1β db-cAMP, foskolin, IBMX PGE2 ↓, 6-keto-PGF1α ↓ [57]
MC3T3-E1 Shear stress mRNA: ↑, promoter: ↑ [52]
Shear stress PKA inhibitor mRNA: ↔, promoter: ↔
Forskolin: mRNA: ↑, promoter: ↑
MC3T3-E1 PTH mRNA: ↑ [53]
PTH Forskolin, 8br-cAMP mRNA: ↑↑
JEG3, trophoblast 8br-cAMP Promoter ↑: mRNA: ↑, PGE2↑ [54]
hEGEC hCG 8-Cl-cAMP Protein: ↑, [55]
8-Br-cAMP Protein: ↔
hEGEC: Human endometrial epithelial gland cells.
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nitroprusside (SNP) substantially increased (3- to 4-fold)
cGMP level but did not affect eicosanoid production. These
results indicate that drugs that enhance cAMP level decrease
PGE2 release fromCOPDmacrophages and stimulate the release
of LTB4, a chemotactic mediator involved in bronchial inflam-
matory reactions.
Pouliot et al. [36] examined the effects of adenosine and
fMLP (formyl methyl leucine proline) on the expression of
COX-2 in human PMNs. Adenosine upregulates the expression
of the COX-2 enzyme and mRNA. Production of PGE2 in
response to exogenous arachidonic acid was also increased by
adenosine and correlated with COX-2 protein levels. This effect
on COX-2 could be mimicked by pharmacological increases of
intracellular cAMP levels, involving the latter as a putative
second messenger for the upregulation of COX-2 by adenosine.
Agents that raise intracellular cAMP levels (S-P-cAMP-
acetoxymethyl: 50 μM; forskolin: 50 μM; Ro20–1724:
10 μM) potentiated the fMLP-stimulated expression of COX-2
protein. S-P-cAMP alone, however, did not stimulate COX-2
protein levels in PMNs. Thus, adenosine may promote a self-
limiting regulatory process through the increase of PGE2
generation, which may result in the inhibition of PMN functions.
Jimenez et al. [37] show that phosphodiesterase (PDE)-4
inhibitors (rolipram, Ro20–1724; N50 μM) block COX-2
induction and prostaglandin synthesis in activated human
T cells. Cells were stimulated with anti-CD3 plus CD28 anti-
bodies, resulting in activation of the NFAT (nuclear factor of
activated T cells) pathway, which can be blocked by calcineurin
inhibitors such as cyclosporine. COX-2 inhibition by PDE4
inhibitors occurs mainly at the transcriptional level. Two
response elements for the nuclear factor of activated T cells
(NFAT) in the COX-2 promoter were required for inhibition by
these drugs. PDE4 inhibitors did not affect NFAT nuclear
translocation upon T cell activation. Rather they prevented
NFAT binding to DNA and induction of the transactivation
function of GAL4-NFAT. These effects seem to be cAMP/PKA
independent as they were not mimicked by db-cAMP or by
forskolin, neither can be reverted by the PKA inhibitors H89 or
KT-5720. These results may explain some of the anti-
inflammatory properties of PDE4 inhibitors through the
blockade of NFAT-mediated transactivation of pro-inflammato-
ry genes such as COX-2.
2.2. Smooth muscle cells, smooth muscle derived cells,
and fibroblasts
It was reported that bradykinin (10 μM) induces COX-2 and
stimulated the release of PGE2 from cultured human pulmonary
artery smoothmuscle cells (hPASMC) [38]. Using the same cells
the authors investigated in a subsequent work the importance of
CRE binding for bradykinin mediated COX-2 induction [39].
EMSA experiments revealed that oligonucleotides specific for
CRE of the COX-2 promoter and consensus oligonucleotides
showed strong specific binding. Furthermore BK increased
p6CRE/luc-mediated luciferase expression. CRE activation
occurred by BK inducing cytosolic phospholipase A2-mediatedarachidonic acid release and rapid PGE2 production, thereby
increasing cAMP. Indomethacin inhibited BK-induced PGE2
production, cAMP accumulation, and CRE/luc reporter and
COX-2 promoter luciferase activity. Exogenous PGE2 (1 μM)
and EP2 (ONO-AE1 259) and EP4 (ONO-AE1 329) PGE2
receptor agonists (10 nM each) mimicked the effect of BK.
Collectively these studies indicate that COX-2 induction by BK
in human pulmonary artery smooth muscle cells is mediated by
the CRE through a novel autocrine loop involving endogenous
PGE2.
Debey et al. [40] studied COX-2 expression in primary
cultures of human arterial smooth muscle cells (hASMC),
derived from coronary artery and aorta. HSMCswere challenged
with PMA (100 nM), and iloprost (100 nM), which acts on the
prostacyclin receptor stimulating adenylate cyclase. Both agents
increased COX-2 mRNA levels. In combination, superinduction
occurred, as evidenced by COX-2 protein levels and COX-2-
dependent synthesis of endogenous prostacyclin. Forskolin
(10 μM) and db-cAMP (1mM) induced COX-2mRNA, albeit to
a smaller extent than iloprost. The authors did not rule out the
possibility that iloprost besides increasing intracellular cAMP
levels acts on COX-2 expression via activation of the ligand
activated transcription factor peroxisome proliferator activated
receptor delta (PPAR-delta) [41]. PPAR-delta promoter con-
structs have been shown to be activated by 10 μM iloprost, but
not by cicaprost. Some weak indirect evidence that iloprost acts
via cAMP signalling in human cells was provided by the fact that
iloprost induces the expression of the transcriptional repressor
ICER (inducible cAMP early repressor), whose expression is
regulated by four CRE sites within the ICER promoter.
Kojima and colleagues [42] analyzed the expression of
COX-2 (and microsomal PGE synthase) in IL-1β-stimulated
human rheumatoid arthritis synovial fibroblast (RASFs) ob-
tained from joint replacement surgery. IL-1β (1 ng/ml) strongly
induced COX-2 protein expression in RASFs. Co-incubation
with a COX-2-selective inhibitor rofecoxib (10 μM) resulted in
modest attenuation of COX-2 expression suggesting that PGE2
acts in positive feedback loop on its own synthesis. Co-
incubation of RASFs with IL-1β and EP2 (ONO-AE1-259) or
EP4 (ONO-AE1-329) selective agonists in the presence of
rofecoxib increased COX-2 mRNA levels compared to IL-1β
and rofecoxib alone. Thus, increased cAMP signalling elicited
by EP2 or EP4 superinduces COX-2 in IL-1β-stimulated
RASFs. The effects of cAMP elevating agents in the absence
of IL-1β were not reported.
In a similar study, Faour and co-workers [43] explored a
positive feedback, PGE2-dependent stabilization of COX-2
mRNA mediated by the p38 MAPK cascade in rhIL-1β
(100 pg/ml)-stimulated human synovial fibroblasts (HSF).
HSF were from synovia harvested at necropsy from donors
with no evidence of arthritis. IL-1 led to a rapid (5 min),
massive (N30-fold), and sustained (N48 h) increase in COX-2
mRNA, protein, and PGE2release that was inhibited by NS-398
(100 ng/ml), a COX-2 inhibitor, and SB202190 (10  g/ml), a
selective, cell-permeable p38 MAPK inhibitor. PGE2(100 nM)
completely reversed NS-398-mediated inhibition but not
SB202190-dependent inhibition. The eicosanoid did not
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COX-2 gene expression in quiescent cells. Transfection experi-
ments with a human COX-2 promoter construct (−2390/+34)
revealed a minor element of p38 MAPK-dependent transcrip-
tional control after IL-1β stimulation. p38 MAPK synergized
with the cAMP/cAMP-dependent protein kinase cascade to
transactivate the COX-2 promoter. When human synovial
fibroblasts were activated with IL-1β for 3–4 h (steady state)
followed by washout, the elevated levels of COX-2 mRNA
declined rapidly (b2 h) to control levels. If PGE2, unlike EP2/3
agonists butaprost and sulprostone (up to 10 μM each), was
added to fresh medium, COX-2mRNA levels remained elevated
for up to 16 h. SB202190 or anti-PGE2 monoclonal antibody
compromised the stabilization of COX-2 mRNA by PGE2.
Deletion analysis using transfected chimeric luciferase–COX-2
mRNA 3′-untranslated region reporter constructs revealed that
IL-1β increased reporter gene mRNA stability and translation
via AU-containing distal regions of the untranslated region. This
response was mediated entirely by a PGE2/p38 MAPK-
dependent process. The authors concluded that the magnitude
and duration of the induction of COX-2 mRNA, protein, and
PGE2 release by rhIL-1β are primarily the result of PGE2-
dependent stabilization of COX-2 mRNA and stimulation of
translation, a process involving a positive feedback loop
mediated by the EP4 receptor and the downstream kinases
p38MAPK and, perhaps, cAMP-dependent protein kinase.
Nusing and colleagues analyzed the effect of dibutyryl cAMP
(db-cAMP) on the regulation and expression of cyclooxygenase-
2, inducible NO synthase and argininosuccinate synthase in rat
renal mesangial cells [44]. Low concentrations of db-cAMP in
the range of 10–50 μM elevated levels of cyclooxygenase-2
mRNA, protein and activity. Prostaglandin E2 stimulated
cyclooxygenase-2 expression and activity at a concentration of
10 μM.
2.3. Endothelial cells
The effects of PGE2 on the induction of COX-2 were studied
in HUVECs treated with IL-1β (1 ng/ml) [45]. COX activity was
measured by the production of 6-keto-PGF1α, PGE2, PGF2α and
thromboxane B2 (TxB2) in the presence of exogenous
arachidonic acid (10 μM for 10 min). Untreated HUVECs
contained only COX-1 protein while IL-1β-treated HUVEC
contained COX-1 and COX-2 protein. PGE2 (3 μM for 24 h) did
not affect COX activity and protein levels in untreated HUVEC.
PGE2 inhibits COX-2 protein, in HUVEC treated with IL-1β.
This inhibition was reversed by co-incubation with forskolin
(100 μM), suggesting that cAMP induces COX-2 in IL-1β-
stimulated HUVECs.
Samokovlisky et al. [46] investigated the effects of cAMP-
elevating agents on COX expression in BAECs. Treatment of
resting BAECs with cAMP-elevating agents inhibited prosta-
cyclin production and COX activity, without affecting arachi-
donic acid release. No change was detected in COX-1 protein
expression. In LPS-treated COX-2 expressing bovine aortic
endothelial cells, COX-2 protein was induced upon treatment
with db-cAMP (1 mM) and further induction of COX-2 proteinwas effected by IBMX (1 mM). These results suggest that
increased cellular cAMP selectively inhibits COX-1 activity
without altering COX-1 protein expression, and at the same
time, upregulates COX-2 protein. This complex regulation of
COX activity and protein expression by cAMP may represent a
prostacyclin-induced autoregulatorymechanism in bovine aortic
endothelial cells.
2.4. Keratinocytes
Tang and co-workers analyzed the effect of UVB irradiation
on the expression of COX-2 in immortalized “normal” human
keratinocytes [47]. Analyses of the COX-2 promoter (−327/+
59) revealed that the CRE site was essential for both basal and
UVB-induced COX-2 expression. Dominant negative mutant of
CREB strongly inhibited the activity of COX-2 promoter.
EMSA indicated that CREB and ATF-1 were the major proteins
binding to the COX-2 CRE. CREB and ATF-1 were phosphor-
ylated upon UVB treatment, and SB202190, a p38MAPK
inhibitor, decreased the phosphorylation of CREB/ATF-1 and
suppressed COX-2 promoter activity. Likewise, treatment with
10 μMforskolin led to phosphorylation of CREB and ATF-1 and
activation of COX-2 promoter.
Maldve et al. [48] demonstrate autoregulation of prostaglan-
din (PG) production by the PGs themselves and their precursor,
AA. 10 μM AA and PGs induced COX-2, as well as COX-1
mRNA, expression in cultured murine keratinocytes approxi-
mately 3 h after treatment. 10 μM forskolin, 100 μM db-cAMP
induced COX-1 and COX-2 mRNA, suggesting that cAMP is a
second messenger for COX expression. 1 μM SQ 22536, an
adenylate cyclase inhibitor, inhibited COX-2 mRNA induction
by PGE2 in a dose-dependent manner suggesting that PGE2-
induced expression may be through one of the cAMP-linked
PGE2 receptors. Further, both COX isoforms can be up regu-
lated by their products, the PGs, and this autoregulation
probably occurs via prostaglandin receptors linked to a cAMP
signal transduction pathway.
2.5. Granulosa cells
So far only non-human cells have been studied. To
understand the molecular mechanisms by which LH regulates
the induction of COX in rat preovulatory (PO) follicles, Wong
et al. [49] established an in vitro system which mimics in vivo
induction of the enzyme. This study was carried out prior to the
discovery of COX-2; most likely the induced COX-isoform,
which migrated slower than “constitutive” COX in granulosa
cells, is COX-2. A rapid increase in COX enzyme (1) is
stimulated by LH, FSH, and 10 μMforskolin in a time- and dose-
dependent manner that is distinct from changes in steroidogenic
enzymes analyzed in the same follicles; (2) is unaltered by end
products (PGE2 and PGF2 ) of the reaction or inhibitors
(indomethacin) of enzyme activity; (3) is blocked by inhibitors
of transcription (alpha-amanitin) and translation (cyclohexi-
mide) at a step distal to production of cAMP and activation of
PKA. In summary, the LH-stimulated appearance of COX in
granulosa cells of PO follicles before ovulation is mediated by
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(COX gene) and translational control of COX mRNA. The
transient appearance of the COX enzyme represents a unique
pattern of response by granulosa cells of PO follicles to LH/
cAMP and thereby may involve novel intracellular factors and
regulatory processes.
Sirois and co-workers [50] studied the effects of LH and FSH
on the regulation of a rat COX-2 promoter construct (−2698/
+32), as well as a series of 5′-deletion mutants in primary
cultures of rat granulosa cells. 7.5 μM Forskolin, FSH (500 ng/
ml), and LH (500 ng/ml) induced CAT activity following
transfection with the −2698/+32 COX-2 construct. Gonadotro-
pin-releasing hormone (10 μM) and 30 ng/ml IL-1β had no
effect. Deletion mutants delineated the region spanning from
−192 to −54 of the transcription start site to be essential for both
basal and forskolin-regulated expression of the reporter gene.
The sameDNA fragment (−192/−54) exhibited specific binding
to granulosa cell nuclear extract proteins as analyzed by EMSA.
Collectively, these results provide the first structural and
functional evidence that the transcriptional regulation of the rat
COX-2 gene by gonadotropins and forskolin in granulosa cells
involves 5′-flanking DNA sequences, specifically a region
between −192 and −54 of the transcription initiation site (CRE
sites).
Wu and Wiltbank [51] elucidated the molecular mechanisms
mediating Cox-2 regulation during differentiation of the bovine
granulosa cell. A −1500/+59 bovine COX-2 promoter construct
vector was transfected into freshly isolated bovine granulosa
cells or granulosa cells after culture with or without 10 μM
forskolin to induce luteinization in vitro. The −1500/+59 COX-
2 promoter was inducible by 1 mM 8-bromo cAMP (but not by
phorbol ester: 10 nM PDD) in fresh granulosa cells, and
maximal expression by cAMP was delayed until 48 h after
treatment. In contrast, after luteinization of granulosa cells by
8-day treatment with forskolin, the COX-2 promoter was imme-
diately inducible by phorbol esters but not by cAMP. In
granulosa cells cultured for 8 days without forskolin, the COX-2
promoter continued to be inducible only by cAMP and not by
phorbol esters. Unexpectedly, no delay was observed in the
induction of COX-2 by cAMP in granulosa cells that were
cultured without forskolin, compared with a 1-day delay in
COX-2 induction by cAMP in fresh granulosa cells. Time-
course experiments showed that only 2 days of forskolin
treatment could induce PKC responsiveness of the COX-2
promoter, although maximal responsiveness was not observed
until 10 days of luteinization. Promoter activity was also
analyzed in a series of deletion mutants as well as site-directed
mutants of C/EBP, CRE, and E-box. A 282-bp sequence in the
COX-2 59 flanking region containing a C/EBP, CRE, and E-box
maintained full inducibility by PKA in granulosa cells and by
PKC in luteinized granulosa cells. The E-box element was found
to be the critical regulatory element for COX-2 induction by
either PKA in granulosa cells or by PKC in luteinized granulosa
cells. In fresh granulosa cells, mutation of the E-box eliminated
the 8-bromo-cAMP-stimulated increase in luciferase activity.
However, mutation in C/EBP, in CRE, or in random sites did not
alter basal or cAMP-stimulated promoter activity. EMSA wereperformed on nuclear extracts from fresh or luteinized granulosa
cells. Upstream stimulatory factor (USF)-1 and USF-2 bound to
the E-box of the COX-2 gene, and binding was similar for
nuclear extracts from fresh, cultured, or luteinized granulosa
cells. Thus, although luteinization changes transcriptional
regulation of COX-2 from PKA to PKC dependence, the crucial
role of the E-box element in this transcriptional activation is
conserved.
2.6. Miscellaneous cell types
Fluid shear stress (FSS) at cell membranes induces new
transcription of cyclooxygenase-2 in murine MC3T3-E1 oste-
oblasts, with peak effects at 4–5 h [52]. Using MC3T3-E1 cells
stably transfected with the murine COX-2 promoter (−370/+
70) fused to a luciferase reporter, Wadhwa et al. examined
involvement of the protein kinase A (PKA) and protein kinase C
(PKC) signalling pathways in the peak COX-2 mRNA and
luciferase responses to FSS (10 dyn/cm2). Neither inhibition nor
downregulation of the PKC pathway affected the FSS
stimulation of COX-2 mRNA or luciferase activity. In contrast,
inhibitors of the PKA (PKI: 1 μM; and H-89: 30 μM) pathway
used at doses, which inhibited forskolin-stimulated (forskolin:
10 μM) luciferase activity by 70–80%, reduced FSS-stimulated
COX-2 mRNA expression and luciferase activity by 50–80%.
Hence, peak FSS induction of COX-2 expression in MC3T3-E1
osteoblastic cells is largely dependent on the PKA signalling
pathway.
Tetradis et al. [53] studied the regulation of COX-2 gene
expression by parathyroid hormone (PTH) and its possible
signalling pathways in osteoblastic MC3T3-E1 cultures. Bovine
PTH (1–34) at 0.01–10 nM increased COX-2, but not COX-1,
messenger RNA (mRNA) levels. The effect of PTH was
maximal at 1 h and decreased almost to control levels by 6 h.
0.1 μM PMA, 10 μM forskolin, and 1 mM 8-bromo-cAMP
increased COX-2 mRNA levels, whereas 1 μM ionomycin had
no effect. PTH, forskolin, and PMA increased the release of
PGE2 into the culture medium. Pre-treatment of cells with
0.1 μM PMA for 16 h blocked the induction of COX-2 mRNA
levels by PMA, but did not alter the effects of PTH and
forskolin. However, treatment of cells with 30 μM H-89, a
protein kinase A inhibitor, significantly reduced the ability of
PTH and forskolin to induce COX-2 mRNA levels. Moreover,
PTH (3–34) at 0.1–100 nM did not induce COX-2 mRNA
levels. These results show that PTH can rapidly and transiently
induce COX-2 mRNA levels in osteoblastic MC3T3-E1 cells,
primarily via the cAMP-protein kinase A signal transduction
pathway.
Anteby et al. [54] examined the regulation of COX isozymes
in human trophoblasts. To this end, primary trophoblasts and
JEG3 cells were transfected with promoter constructs of either
human COX-1 (Š 789/+9) or COX-2 (Š 891/+9) genes. In both
cell systems, the basal activity of COX-2 promoter was 10- to
30-fold higher than the activity of COX-1 promoter. In response
to either 25 ng/ml TPA, or 1 mM 8-bromo-cAMP, an increase in
COX-2 promoter activity but no change in activity of COX-1
promoter was observed. Similarly, both agents enhanced COX-2
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promoter was potentiated by co-expression of protein kinase A
and inhibited by co-expression of kinase A inhibitor. Aspirin
attenuated the stimulatory effect of TPA on COX-2 promoter.
The activity of COX-2 promoter is stimulated by either TPA or
cAMP, and the stimulatory effect of TPA is attenuated by aspirin.
These pathways may play a role in modulation of prostanoid
synthesis by trophoblasts.
Zhou and colleagues [55] examined the effects of recombi-
nant hCG (human chorionic gonadotropin) on primary cultures
of human endometrial epithelial gland cells. hCG dose
dependently (10–100 ng/ml) induced the expression of COX-
2 mRNA (200%), protein (150%), and stimulated PGE2 (200%)
secretion. Since hCG is known to increase intracellular cAMP
levels and thus activates PKA-dependent pathways, the effects
of the PKA inhibitor H89 (50 nM), and Bis, a PKC inhibitor
(50 nM), were studied. In contrast to Bis, H89 almost com-
pletely blunted induction of COX-2 mRNA and protein by
hCG. In the absence of hCG induction of COX-2 protein was
also observed with 8-Br-cAMP (0.1 mM), but did not occur
with the PKA inhibitor 8-Cl-cAMP (0.1 mM).
Results from experiments done in-house using cytokine-
stimulated A549 (human epithelial cells) demonstrated no effect
of forskolin (10 μM), RP73401 (1 μM) or db-cAMP (1 mM) on
PGE2 synthesis by its own or in combination with cytokines
(Mais and Klein 2004, unpublished observation). Yang and
Bleich [56] used murine pancreatic β-cells (RINm5F) to
explore the molecular mechanisms regulating COX-2 promoter
activity. Through deletion analysis of a −907/+70-bp 5′ up-
stream region of the mouse COX-2 gene, they identified an
inhibition domain (−804/−371) and an activation domain
(−371/+70). The highest promoter activity was seen when the
promoter was reduced to Š 371 bp. Three sites were identified in
the Š 371 construct that were essential for basal COX-2 pro-
moter activity: (1) C/EBP, (2) aryl hydrocarbon receptor (AhR),
and (3) CREB. Single mutation of each individual site inhibited
70… 80% of basal COX-2 promoter activity. Double mutation of
the AhR and CREB-binding sites showed synergy in repressingFig. 3. Inhibitory effect of cAMP mimetics on IL-1β (1 nM) stimulated 6-keto
PGF1α synthesis in primary human chondrocytes. Compounds were pre-
incubated 30 min prior IL-1β stimulation and incubated for 24 h. 6-keto PGF1α
was analyzed via GC/MS spectrometry. Values represent means (ng/ml)±S.E.M.
of 3 different donors.COX-2 promoter activity, as did mutation of all three sites.
Transcription factors from RINm5F nuclear extracts specifically
bound to oligonucleotides containing C/EBP, AhR, or CREB
consensus sites. 10 μM forskolin increased COX-2 promoter
activity via the CREB site. COX-2 promoter activity was also
increased by 10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin, an
AhR activator, through the AhR site.
In in-house experiments, we could show that PG synthesis in
human chondrocytes is regulated by cAMP: using various
modulators of cAMP signalling we could achieve a down-
regulation of 6-keto-PGF1α and PGE2 synthesis. RP-73401, a
selective PDE4i (1 μM), IBMX (300 μM), forskolin (10 μM)
and db-cAMP (1 mM) lowered the IL-1β evoked 6-keto-PGF1α
production to about 50% (Fig. 3). Similar effects on human
chondrocytes were described from Tenor et al. [57] on the IL-1β
induced PGE2 production.
3. Summary and concluding remarks
Analysis of the human COX-2 promoter in various cell types
revealed the critical importance of the CRE site for COX-2 gene
expression. This response element is the downstream endpoint
for a large variety of stimuli, encompassing classical inflam-
matory signals (i.e., IL-1β, LPS), shear stress, ceramide, and
others at the transcriptional level. However, there is consider-
ably less evidence that cAMP signalling plays a major role in
the post-transcriptional regulation of COX-2 protein.
Various studies showed that activation of the cAMP
signalling pathway alone may increase COX-2 mRNA and/or
protein expression, albeit mostly at a modest level compared to a
combined exposure: alone, cAMP modifiers induced COX-2
expression in the following cell types: RAW264.7 cells (db-
cAMP [58]); human coronary artery endothelial cells, primary
neonatal rat cardiomyocyte cultures, and RAW264.7 mouse
macrophages (milrinone [59]); rat microglia (db-cAMP, for-
skolin [60]); human coronary arterial smooth muscle cells
(forskolin, db-cAMP [61]), rat renal mesangial cells (db-cAMP
[44]), murine keratinocytes (forskolin, db-cAMP [48]), osteo-
blastic MC3T3-E1 cultures (forskolin, 8br-cAMP [53]), human
trophoblasts (8br-cAMP [54] ), human endometrial epithelial
gland cells (8br-cAMP [55]), rat preovulatory follicles (forskolin
[49]). Transcriptional activation of COX-promoter constructs
by cAMP elevating agents was observed in murine pancreatic
β-cells (forskolin [56]), rat granulosa cells (forskolin [50]),
bovine granulosa cell (8br-cAMP, forskolin [51]).
An attenuation of COX-2 expression following treatment
with cAMP modifiers was observed in three studies [35,37] and
was also evident from our own studies using human chondro-
cytes. In the Jimenez study, NFAT-dependent COX-2 gene
expression was probably unrelated to cAMP levels increased by
either rolipram, etazolate, or Ro20–1724.
Collectively, the majority of studies indicate that COX-2
expression is induced by cAMP elevating agents. This effect is
observed in all species, and with very few exceptions in all cell
types studied. The majority of data indicate that cAMP in vitro
mainly superinduces COX-2 expression when a given
(inflammatory) stimulus is already present. cAMP must
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expression, rather than an inducer. This may indicate that
clinical use of, e.g., β2-mimetics or PG receptors agonists in
the absence of active inflammatory processes will not impact
significantly on COX-2-dependent production of prostanoids.
However, it may be conceivable that these pharmacological
agents may augment COX-2 activity in patients with active
inflammatory diseases. Nonetheless COX-2 derived prosta-
noids show protective (e.g., acceleration of ulcer heeling) as
well as detrimental (e.g., rheumatic arthritis) effects on the
organism. The therapeutics pros and cons of elevations of
COX-2 levels will therefore have to be established on a case-to-
case basis.
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